4.7 Article

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 64, Issue 11, Pages -

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01433-20

Keywords

Gram-negative bacteria; Stenotrophomonas maltophilia; aztreonam-avibactam; bloodstream infections; nonfermentative; trimethoprim-sulfamethoxazole

Funding

  1. Pfizer Inc. (New York, NY)

Ask authors/readers for more resources

Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC50/90, 4/4 mg/liter; 97.8% inhibited at <= 8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC50/90, <= 0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC50/90, 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at <= 8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of S. maltophilia infections, addressing a major unmet medical need.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available